Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Ofloxacin (ausschl. Dafo. KPG), ATC S01AE01 f. d. Z. 01.08.2026 - 31.07.2028 (zzgl. V.-Option 1x12 Monate)

Section 130a, paragraph 8, SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract for the aforementioned active substance Ofloxacin (exclusively in the dosage form KPG), ATC S01AE01, the DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount contracts. A discount contract under the licensing model for the aforementioned active substance comes into force for the first time on 01.08.2026 and ends on 31.07.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.